Also found in: Dictionary.


Apo-Meloxicam (CA), Co Meloxicam (CA), Dom-Meloxicam (CA), Gen-Meloxicam (CA), Mobic, Mobicox (CA), Novo-Meloxicam (CA), PHL-Meloxicam (CA), Ratio-Meloxicam (CA)

Pharmacologic class: Nonopioid analgesic, nonsteroidal anti-inflammatory drug (NSAID)

Therapeutic class: Analgesic, anti-inflammatory drug

Pregnancy risk category C

FDA Box Warning

• Drug may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke. Risk may increase with duration of use. Patients with cardiovascular disease or risk factors for it may be at greater risk.

• Drug increases risk of serious GI adverse events, including bleeding, ulcers, and stomach or intestinal perforation. These events can occur at any time during use and without warning. Elderly patients are at greater risk.

• Drug is contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery.


Unknown. Thought to reduce inflammation and pain by inhibiting prostaglandin synthesis of the enzyme cyclooxygenase.


Oral suspension: 7.5 mg/5 ml

Tablets: 7.5 mg, 15 mg

Indications and dosages

Osteoarthritis; rheumatoid arthritis

Adults: 7.5 mg P.O. once daily; may increase to 15 mg/day

Juvenile arthritis

Children ages 2 and older: 0.125 mg/kg P.O. once daily, up to a maximum of 7.5 mg


• Hypersensitivity to drug, its components, or other NSAIDs


Use cautiously in:
• bleeding disorders, GI or cardiac disorders, severe renal impairment, severe hepatic disease, asthma, peptic ulcer disease
• concurrent aspirin, oral anticoagulant, or corticosteroid therapy
• elderly or debilitated patients
• pregnant or breastfeeding patients.


• Before starting therapy, ask patient about aspirin sensitivity and allergies to other NSAIDs. If patient is dehydrated, provide adequate fluids.

Adverse reactions

CNS: headache, dizziness, syncope, malaise, fatigue, asthenia, depression, confusion, nervousness, drowsiness, insomnia, vertigo, tremor, paresthesia, anxiety, seizures

CV: hypertension, hypotension, palpitations, angina, vasculitis, heart failure, arrhythmias, MI

EENT: abnormal vision, conjunctivitis, hearing loss, tinnitus, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, colitis, GI ulcers with perforation, abdominal pain, dyspepsia, gastroesophageal reflux, esophagitis, flatulence, ulcerative stomatitis, dry mouth, pancreatitis, GI hemorrhage

GU: urinary frequency, urinary tract infection, albuminuria, hematuria, renal failure

Hematologic: anemia, purpura, leukopenia, thrombocytopenia

Hepatic: hepatitis

Musculoskeletal: joint pain, back pain

Metabolic: dehydration

Respiratory: upper respiratory infection, dyspnea, coughing, asthma, bronchospasm

Skin: rash, urticaria, pruritus, bullous eruption, sweating, alopecia, photosensitivity, angioedema

Other: altered taste, increased appetite, weight gain or loss, hot flashes, fluid retention and edema, masking of infection symptoms, hypersensitivity reactions including anaphylaxis


Drug-drug.Angiotensin-converting enzyme inhibitors: decreased antihypertensive effect

Anticoagulants: increased risk of bleeding

Aspirin: increased meloxicam blood level, increased risk of toxicity

Cholestyramine: decreased meloxicam blood level

Furosemide, thiazides: decreased diuretic effect

Lithium: increased lithium blood level

Drug-diagnostic tests.Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, gamma-glutamyl transferase: increased levels

Hemoglobin, platelets, white blood cells: decreased values

Drug-behaviors.Alcohol use, smoking: increased risk of GI irritation and bleeding

Patient monitoring

Closely monitor patient with aspirin-sensitivity asthma, because of risk of severe bronchospasm.
• In prolonged therapy, monitor CBC and kidney and liver function tests.

Assess for cardiovascular disorders and hepatotoxicity.
• Monitor patient for fluid retention and weight gain.

Patient teaching

Instruct patient to immediately report signs and symptoms of hepatotoxicity, including right upper quadrant pain, nausea, fatigue, lethargy, pruritus, and jaundice.
• Tell patient to report abdominal pain, blood in stool or emesis, or black tarry stools.
• Instruct patient to avoid alcohol and smoking.
• Caution pregnant patient to avoid drug, especially during third trimester.
• Tell patient to consult prescriber before taking over-the-counter preparations.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.


A trademark for the drug meloxicam.


An oral NSAID used for osteoarthritis.


; Mobic non-steroidal anti-inflammatory drug used to control pain and inflammation in rheumatoid disease, ankylosing spondylitis and exacerbations of osteoarthritis
Mentioned in ?
References in periodicals archive ?
Pooling resources allowed companies like AffordRx to offer steep discounts with Mobic coupons and more, helping patients who could not otherwise afford their medication.
They include celecoxib (Celebrex), mobic (Meloxicam) and Bextra (valdecoxib).
The medications are celecoxib (Celebrex) approved to treat osteoarthritis and rheumatoid arthritis and mobic (Meloxicam) approved for osteoarthritis.
But there doesn't seem to be much interest in pushing others, like Mobic, which is similar in effectiveness.
Now there is Mobic (or meloxicam) for the treatment of the symptoms of osteoarthritis.
The Coventry firm is part of the MOBIC consortium, whose other partners include WS Atkins, Racal, Logica and TransCore.
Q I take Mobic Melepiam every day for shoulder arc syndrome but I was wondering if there was an alternative I could use.
Fischette's extensive track record spans both launch and life cycle management of a number of products, including Subpart H brands such as EXJADE an oral iron chelator and the COX-2 inhibitor franchise, which included Vioxx and Arcoxia, for Merck and of Mobic, a joint venture of Abbott pharmaceuticals and Boeheringer Ingelheim.
Roy Altman, chief of the arthritis division at the University of Miami, said that Mobic is "somewhat selective" but not a specific inhibitor of cyclooxygenase (COX)-2, which produces pain-mediating prostaglandins.
Prior to this role, she had over ten years of marketing experience where she led several brand launches including Mobic, an NSAID which became a $1 billion dollar brand.
In 2006, Medco's clients and its nearly 60 million members saved $392 million from patent expirations of several blockbuster drugs including Zocor (simvastatin), Zoloft (sertraline), Pravachol (pravastatin), Flonase (fluticasone propionate) and Mobic (meloxicam).
Evaluate the impact of generic competition for the key product Flomax, particularly in light of recent patent expiry for another key product, Mobic